



# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/796,925	03/10/2004	Wumin Li	AM 101333	3270
25291	7590	05/30/2008		
WYETH PATENT LAW GROUP 5 GIRALDA FARMS MADISON, NJ 07940			EXAMINER TONGUE, LAKIA J	
			ART UNIT 1645	PAPER NUMBER
			MAIL DATE 05/30/2008	DELIVERY MODE PAPER

**Please find below and/or attached an Office communication concerning this application or proceeding.**

The time period for reply, if any, is set in the attached communication.

<b>Office Action Summary</b>	<b>Application No.</b> 10/796,925	<b>Applicant(s)</b> LI ET AL.	
	<b>Examiner</b> LAKIA J. TONGUE	<b>Art Unit</b> 1645	

**-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --**

### Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

### Status

- 1) ☒ Responsive to communication(s) filed on 18 January 2008.
- 2a) ☒ This action is **FINAL**.                      2b) ☐ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

### Disposition of Claims

- 4) ☒ Claim(s) 22-24 is/are pending in the application.
- 4a) Of the above claim(s) \_\_\_\_\_ is/are withdrawn from consideration.
- 5) ☐ Claim(s) \_\_\_\_\_ is/are allowed.
- 6) ☒ Claim(s) 22-24 is/are rejected.
- 7) ☐ Claim(s) \_\_\_\_\_ is/are objected to.
- 8) ☐ Claim(s) \_\_\_\_\_ are subject to restriction and/or election requirement.

### Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on \_\_\_\_\_ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.  
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).  
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

### Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All    b) ☐ Some \*    c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
  2. ☐ Certified copies of the priority documents have been received in Application No. \_\_\_\_\_.
  3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

\* See the attached detailed Office action for a list of the certified copies not received.

### Attachment(s)

- |  |   |
|--|---|
| 1) <input checked="" type="checkbox"/> Notice of References Cited (PTO-892)          | 4) <input type="checkbox"/> Interview Summary (PTO-413)           |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948) | Paper No(s)/Mail Date. _____                                      |
| 3) <input type="checkbox"/> Information Disclosure Statement(s) (PTO/SB/08)          | 5) <input type="checkbox"/> Notice of Informal Patent Application |
| Paper No(s)/Mail Date _____  | 6) <input type="checkbox"/> Other: _____                          |

### **DETAILED ACTION**

The amendment of January 18, 2008 is acknowledged. Claim 22-24 are pending. Claim 22 has been amended. Claims 22-24 are currently under examination.

#### ***Rejections Withdrawn***

1. In view of Applicant's amendment and arguments, the rejection of claims 22-24 under 35 U.S.C. 103(a) as being unpatentable over Doyle et al. (U.S. Patent 5,965,128), in view of Clancy et al. (U.S. 2004/0057965 A1), and further in view of the SIGMA Catalog (Biochemicals and Reagents for life science, 2000-2001, Adjuvants, pages 1472) is withdrawn. The fact that Doyle et al. does not teach or suggest parenteral injections obviates said rejection.

2. In view of Applicant's amendment and arguments, the rejection of claims 22-24 under 35 U.S.C. 103(a) as being unpatentable over Doyle et al. (U.S. Patent 5,965,128), in view of Clancy et al. (U.S. 2004/0057965 A1), and further in view of the SIGMA Catalog (Biochemicals and Reagents for life science, 2000-2001, Adjuvants, 1472), and further in view of Molly et al. (U.S. 2005/0084500 A1) is withdrawn. The fact that Doyle et al. does not teach or suggest parenteral injections obviates said rejection.

3. In view of Applicant's amendment and the rejection set forth below the rejection of claim 22 under 35 U.S.C. 103(a) as being unpatentable over Johnson et al. (Effect of dairy calves with an inactivated *E. coli* O157:H7 bacterin on shedding of *E. coli*

O157:H7, 1999; Abstract 40 aP), in view of SIGMA (Biochemicals and Reagents for life science, 2000-2001, Adjuvants, 1472) is withdrawn.

4. In view of Applicant's amendment, the rejection of claim 24 under 35 U.S.C. 112, first paragraph, as failing to comply with the written description requirement is withdrawn.

***New Grounds of Objection/Rejection Necessitated by Amendment***

***Claim Objections***

5. Claim 22 is objected to because of the following informalities: upon its first recitation the acronym "SP oil" should be followed by the components that are present in the SP oil (i.e. an oil emulsion comprising a polyoxyethylene-polyoxypropylene block copolymer, squalane, polyoxyethylene sorbitan monooleate and a buffered salt solution). Appropriate correction is required.

***Claim Rejections - 35 USC § 112***

The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

6. Claims 22-24 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

Claim 22 is rendered vague and indefinite by the use of the terms "SP oil". It is

Art Unit: 1645

unclear what is meant by said terms, as it is not explicitly defined in the specification.

What constitutes “SP oil”? The specification discloses that the term “SP oil” designates an oil emulsion comprising a polyoxethylene-polyoxypropylene block polymer, squalane, polyoxyethylene sorbitan monooleate and a buffered salt solution (see page 6, lines 4-6). However, in Example 1, the formulation of SP oil only discloses polyoxethylene-polyoxypropylene block polymer, under the trade name Pluronic® L121 and Squalane. Are all components identified on page 6 of the specification necessary to be considered SP oil or is any one of the four components considered SP oil? As written, it is impossible to determine the metes and bounds of the claimed invention.

### ***Claim Rejections - 35 USC § 103***

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

Johnson et al. was used for a rejection in the previous Office action. Applicant's pertinent arguments are addressed below.

7. Claims 22 and 24 are rejected under 35 U.S.C. 103(a) as being unpatentable over Johnson et al. (Effect of dairy calves with an inactivated *E. coli* O157:H7 bacterin on shedding of *E. coli* O157:H7, 1999; Abstract 40 aP), Saito et al. (U.S. 2005/0158330 A1), and Baylor et al. (Vaccine, 2002; 20: S18-S23).

The rejected claims are drawn to a method for reducing shedding of *E. coli* O157:H7 in an animal which comprises administering by parenteral injection to the animal an effective amount of a vaccine composition containing *E. coli* O157:H7, wherein the vaccine composition comprises inactivated or killed *E. coli* O157:H7, an adjuvant comprising SP oil and aluminum hydroxide, and optionally a pharmaceutically acceptable carrier.

Johnson et al. disclose a study to determine the effect of vaccinating dairy calves with an inactivated *Escherichia coli* O157:H7 bacterin on the shedding of *Escherichia coli* O157:H7 (see title). Johnson et al. disclose that six newly weaned calves were vaccinated intramuscularly with an inactivated *E. coli* O157:H7 bacterin. Moreover, Johnson et al. disclose that the shedding of the organism by most calves in each group fell to 50 CFU/g of feces within 2-3 weeks of challenge (see abstract).

Johnson et al. does not specifically disclose an adjuvant comprising SP oil and aluminum hydroxide.

Saito et al. disclose oil adjuvant vaccines which include sorbitan fatty acid ester (e.g., sorbitan monooleate, etc.), non-ionic surfactants, having a polyoxyethylene chain in a molecule, such as polyoxyethylene sorbitan fatty acid ester polysorbate (e.g., polyoxyethylene(20)sorbitan monooleate etc.), polyoxyethylene polyoxypropylene glycol and the like (see paragraph 0034). Saito et al. disclose that the vaccine comprise antigens of inactivated cells from Gram negative bacteria such as *Escherichia coli* (see paragraph 0044). Moreover, the vaccine may contain, in addition to an antigen, an efficacious component such as an antibiotic (see paragraph 0045). Saito et al. disclose

that suitable administration routes include subcutaneous, intramuscular and intraperitoneal injections (see paragraph 0066).

Saito et al. do not specifically disclose the use of aluminum hydroxide.

It would have been obvious to one of ordinary skill in the art at the time of invention to modify the invention of Johnson et al. with the teachings of Saito et al. because Saito et al. disclose a vaccine which comprises inactivated cells of *E. coli* antigen coupled with an adjuvant comprising the components of SP oil. Further, it would have been obvious to one of ordinary skill in the art at the time of invention to modify the invention of Johnson et al. with the teachings of Saito et al. to use inactivated whole *E. coli* O157:H7 because it is highly potent and can cause severe infections. It would have been obvious to use the components together along with aluminum hydroxide because aluminum hydroxide is a known adjuvant that is well known in the art to stimulate an immune response. See Baylor et al., which disclose that aluminum hydroxide has been commonly used as an adjuvant in many vaccines for decades and have been proven safe (see abstract and page S21-Summary).

It would have been expected, barring evidence to the contrary, that the composition would be effective in reducing shedding of *E. coli* O157:H7 because all the claimed elements were known in the prior art and one skilled in the art could have combined the elements as claimed with no change in their respective functions, and the combination would have yielded predictable results to one of ordinary skill in the art at the time of the invention (KSR International Co. v. Teleflex inc., 500 U.S.-, 82 US{Q2d 1385 (2007). Moreover, KSR forecloses the argument that a **specific** teaching,

Art Unit: 1645

suggestion, or motivation is required to support a finding of obvious. See the recent Board decision *Ex parte Smith*,--USPQ2d--, slip op. at 20, (Bd. Pat. App. & Interf. June 25, 2007) (citing *KSR*, 82 USPQ2d at 1396).

The method of the prior art is the same as that which has been claimed, consequently, the method necessarily produces minimal injection site reaction.

Applicant argues that:

1) One would see a totally different vaccine composition taught by Johnson et al. than recited in the instant claims as there is scientific basis for the inclusion and requirement of the inactivated verotoxin 2 and intimin O157.

2) It is interesting to find that others do not hold the same opinion as the Examiner, which is that Johnson et al. fails to reduce shedding.

Applicant's arguments have been considered, but are not persuasive.

With regard to Point 1, the instant claim recite open claim language and thus does not exclude other materials (i.e. inactivated verotoxin 2 and intimin O157) from being present in the claimed composition. Moreover, Johnson et al. disclose that shedding of the organism by most calves in each group fell to <50 CFU/g of feces within 2-3 weeks of challenge, thus meeting the limitation of reducing shedding of *E. coli* O157:H7 in an animal and meeting the requirement of a reasonable expectation of success.

With regard to Point 2, Applicants assertion that others do not agree with the Examiner in the holding of the argument that Johnson et al. reduces shedding of *E. coli*



O157:H7 is noted. However, given that Applicant has provided no opinion, in declaration form, said assertion is deemed non-persuasive. Moreover, the passage cited by Applicant makes no reference to the work of Johnson et al. Finally, contrary to Applicant's arguments, Johnson et al. disclose that after the administration of inactivated *E. coli* O157:H7 shedding fell to <50 CFU/g of feces within 2-3 weeks of challenge thereby meeting the limitation of reducing shedding of *E. coli* O157:H7.

8. Claims 22-24 are rejected under 35 U.S.C. 103(a) as being unpatentable over Johnson et al. (Effect of dairy calves with an inactivated *E. coli* O157:H7 bacterin on shedding of *E. coli* O157:H7, 1999; Abstract 40 aP), in view of Saito et al. (U.S. 2005/0158330 A1), in view of Baylor et al. (Vaccine, 2002; 20: S18-S23) as set forth above and further in view of Elder et al. (Journal of Animal Science, 2002; 80 (sup. 1): 151 (abstract 602)).

The rejected claims are drawn to a method for reducing shedding of *E. coli* O157:H7 in an animal which comprises administering by parenteral injection to the animal an effective amount of a vaccine composition containing *E. coli* O157:H7, wherein the vaccine composition comprises inactivated or killed *E. coli* O157:H7, an adjuvant comprising SP oil and aluminum hydroxide, and optionally a pharmaceutically acceptable carrier. Subsequent claim 23 is drawn to a method that further comprises administering an effective amount of *Lactobacillus acidophilus* or neomycin medicated feed supplement to the animal.

Johnson et al., Saito et al., and Baylor et al. disclose the limitations of claims 22 and 24 above. Johnson et al., Saito et al., and Baylor et al. do not specifically disclose that the method further comprises administering an effective amount of *Lactobacillus acidophilus* or neomycin medicated feed to the animal.

As set forth above, Johnson et al. disclose a study to determine the effect of vaccinating dairy calves with an inactivated *Escherichia coli* O157:H7 bacterin on the shedding of *Escherichia coli* O157:H7 (see title). Johnson et al. disclose that six newly weaned calves were vaccinated intramuscularly with an inactivated *E. coli* O157:H7 bacterin. Moreover, Johnson et al. disclose that the shedding of the organism by most calves in each group fell to 0 CFU/g of feces within 2-3 weeks of challenge (see abstract).

Johnson et al. does not specifically disclose an adjuvant comprising SP oil and aluminum hydroxide or the optional pharmaceutically acceptable carrier.

Saito et al. disclose oil adjuvant vaccines which include sorbitan fatty acid ester (e.g., sorbitan monooleate, etc.), a non-ionic surfactant, having a polyoxyethylene chain in a molecule, such as polyoxyethylene sorbitan fatty acid ester polysorbate (e.g., polyoxyethylene(20)sorbitan monooleate etc.), polyoxyethylene polyoxypropylene glycol and the like (see paragraph 0034). Saito et al. disclose that the vaccine comprises antigens of inactivated cells from Gram negative bacteria such as *Escherichia coli* etc. (see paragraph 0044). The vaccine may contain, in addition to an antigen, an efficacious component such as an antibiotic (see paragraph 0045). Moreover, Saito et

al. disclose that suitable administration routes include subcutaneous, intramuscular and intraperitoneal injections (see paragraph 0066).

Saito et al. do not specifically disclose the use of aluminum hydroxide.

Elder et al. disclose an intervention to reduce fecal shedding of *E. coli* O157:H7 in naturally infected cattle when administered neomycin (see page 151, abstract 602).

It would have been obvious to one of ordinary skill in the art at the time of invention to modify the teachings of Johnson et al., Saito et al., and Baylor et al. with the teachings of Elder et al. because it is obvious to combine two compositions (neomycin and inactivated or killed whole *E. coli* O157:H7) each of which is taught by the prior art to be useful for the same purpose, in order to form a third composition to be used for the very same purpose.... [T]he idea of combining them flows logically from their having been individually taught in the prior art." *In re Kerkhoven*, 626 F.2d 846, 850, 205 USPQ 1069, 1072 (CCPA 1980). Providing the composition as a medicated feed would be obvious because it provides a more convenient means of delivery and would be more suitable for the improvement of intestinal function when fed to dairy animals such as cows, goats and ewes.

It would have been expected, barring evidence to the contrary, that the composition would be effective because all the claimed elements were known in the prior art and one skilled in the art could have combined the elements as claimed with no change in their respective functions, and the combination would have yielded predictable results to one of ordinary skill in the art at the time of the invention (KSR International Co. v. Teleflex inc., 500 U.S.-, 82 US{Q2d 1385 (2007). Moreover, KSR

Art Unit: 1645

forecloses the argument that a **specific** teaching, suggestion, or motivation is required to support a finding of obviousness. See the recent Board decision *Ex parte Smith*,-- *USPQ2d*--, slip op. at 20, (Bd. Pat. App. & Interf. June 25, 2007) (citing *KSR*, 82 *USPQ2d* at 1396).

### ***Conclusion***

9. No claim is allowed.

10. Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, **THIS ACTION IS MADE FINAL**. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the date of this final action.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to LAKIA J. TONGUE whose telephone number is (571)272-2921. The examiner can normally be reached on Monday-Friday 8-5:30.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Shanon Foley can be reached on 571-272-0898. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

LJT  
5/13/08

/Robert A. Zeman/

for Lakia J. Tongue, Examiner of Art Unit 1645

May 27, 2008